Immunotherapy advances for mesothelioma treatment

References

• Inai K. Pathology of mesothelioma. Environ Health Prev Med. 2008;13(2):60–64.
   PubMedGoogle Scholar
• Mott FE. Mesothelioma: a review. Ochsner J. 2012;12(1):70–79.
   PubMedGoogle Scholar
• Nabavi N, Bennewith KL, Churg A, et al. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer. 2016;7(11–12):340–354.
   PubMedGoogle Scholar
• Mutti L. Malignant pleural mesothelioma: new ideas needed. Lung Cancer Manag. 2015;4(5):201–203.
   Web of Science ®Google Scholar
• Guazzelli A, Bakker E, Krstic-Demonacos M, et al. Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy. 2017;9(3):273–280.
   PubMed Web of Science ®Google Scholar
• Rivera Z, Strianese O, Bertino P, et al. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008;14(4):316–321.
   PubMed Web of Science ®Google Scholar
• Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths and hypotheses. J Cell Physiol. 2012;227(1):44–58.
   PubMed Web of Science ®Google Scholar
• Goodman JE, Nascarella MA, Valberg PA. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control. 2009;20(8):1237–1254.
   PubMed Web of Science ®Google Scholar
• Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.
   PubMed Web of Science ®Google Scholar
• Linton A, van Zandwijk N, Reid G, et al. Inflammation in malignant mesothelioma - friend or foe? Ann Cardiothorac Surg. 2012;1(4):516–522.
   PubMedGoogle Scholar
• Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006;103(27):10397–10402.
   PubMed Web of Science ®Google Scholar
• Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010;107(28):12611–12616.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–1025.
   PubMed Web of Science ®Google Scholar
• Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis. 2008;3(1):34.
   PubMed Web of Science ®Google Scholar
• Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125(2):489–493.
   PubMed Web of Science ®Google Scholar
• Ismail-Khan R, Robinson LA, Williams CC Jr., et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255–263.
   PubMedGoogle Scholar
• Fennell DA, Gaudino G, O’Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5(3):136–147.
   PubMedGoogle Scholar
• Rusch V. ED05.02 update on the mesothelioma staging system. J Thorac Oncol. 2017;12(1):S30–S31.
   Google Scholar
• Neumann V, Loseke S, Nowak D, et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013;110(18):319–326.
   PubMed Web of Science ®Google Scholar
• Belli C, Fennell D, Giovannini M, et al. Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs. 2009;14(3):423–437.
   PubMed Web of Science ®Google Scholar
• Guazzelli A, Hussain M, Krstic-Demonacos M, et al. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819–1829.
   PubMed Web of Science ®Google Scholar
• Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2(10):957–965.
   PubMed Web of Science ®Google Scholar
• Baskar R, Lee KA, Yeo R, et al. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–199.
   PubMed Web of Science ®Google Scholar
• Rosenzweig KE, Giraud P. Radiation therapy for malignant pleural mesothelioma. Cancer Radiotherapie. 2017;21(1):73–76.
   PubMed Web of Science ®Google Scholar
• Pinton G, Manente AG, Tavian D, et al. Therapies currently in Phase II trials for malignant pleural mesothelioma. Expert Opin Investig Drugs. 2013;22(10):1255–1263.
   PubMed Web of Science ®Google Scholar
• Remon J, Reguart N, Corral J, et al. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41(1):27–34.
   PubMed Web of Science ®Google Scholar
• Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007;62(8):690–695.
   PubMed Web of Science ®Google Scholar
• Berger MS, Weller M. Gliomas. Amsterdam, Netherlands: Elsevier Science; 2016.
   Google Scholar
• Bix M, Liao NS, Zijlstra M, et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 1991;349(6307):329–331.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Linking innate to adaptive immunity through dendritic cells. Novartis Found Symp. 2006;279:101-109; discussion 109-113, 216-109.
   PubMedGoogle Scholar
• Deauvieau F, Ollion V, Doffin AC, et al. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer. 2015;136(5):1085–1094.
   PubMed Web of Science ®Google Scholar
• Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S33–S40.
   PubMed Web of Science ®Google Scholar
• Bograd AJ, Suzuki K, Vertes E, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunotherapy. 2011;60(11):1509–1527.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73.
   PubMed Web of Science ®Google Scholar
• Bakker E, Guazzelli A, Krstic-Demonacos M, et al. Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs. 2017;5(6):455–465.
   Web of Science ®Google Scholar
• Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J. 1982;61(26):1007–1009.
   PubMed Web of Science ®Google Scholar
• Grégoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr. 2010;4(1):153–161.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Hemmes A, Aerts JG, et al. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005;171(10):1168–1177.
   PubMed Web of Science ®Google Scholar
• Papaioannou NE, Beniata OV, Vitsos P, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4:14.
   PubMed Web of Science ®Google Scholar
• Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(10):1467–1479.
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116(2):171–179.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181(12):1383–1390.
   PubMed Web of Science ®Google Scholar
• Berneman ZN, Germonpre P, Huizing MT, et al. Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study. Journal of Clinical Oncology. 2014;32:7583–7583.
   Web of Science ®Google Scholar
• Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016;193(9):1023–1031.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Haas AR, Metzger S, et al. Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE). Journal of Clinical Oncology. 2016;34:3081–3081.
   Web of Science ®Google Scholar
• Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011;34(7):556–567.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Chuk MK, Chang JT, Theoret MR, et al. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res. 2017.
   Web of Science ®Google Scholar
• Kindler HL, Scherpereel A, Calabrò L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. Journal of Clinical Oncology. 2016;34:8502–8502.
   Web of Science ®Google Scholar
• Alley EW, Molife LR, Santoro A, et al. Abstract CT103: clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. Cancer Res. 2015;75(15 Supplement):CT103–CT103.
   Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–630.
   PubMed Web of Science ®Google Scholar
• Thapa B, Walkiewicz M, Rivalland G, et al. Immune microenvironment in mesothelioma: looking beyond PD-L1. J Clin Oncol. 2017;35(15_suppl):8515–8515.
   Google Scholar
• Thapa B, Watkins DN, John T. Immunotherapy for malignant mesothelioma: reality check. Expert Rev Anticancer Ther. 2016;16:1–10.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Klieser E, Neureiter D, et al. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signaling. 2017;15(1):1.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respi Med. 2015;3(4):301–309.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–1111.
   PubMed Web of Science ®Google Scholar
• Kelly K, Heery CR, Patel MR, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. Journal of Clinical Oncology. 2016;34:3055–3055.
   Google Scholar
• Boisgerault N, Achard C, Delaunay T, et al. Oncolytic virotherapy for human malignant mesothelioma: recent advances. Oncolytic Virother. 2015;4:133–140.
   PubMedGoogle Scholar
• Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998;83(10):2099–2104.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541–1549.
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Kindler HL, Papasavvas E, et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013;2(8):e26218.
   PubMed Web of Science ®Google Scholar
• Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin expressing cancers. Clin Cancer Res. 2010;16(24):6132–6138.
   PubMed Web of Science ®Google Scholar
• Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014;120(21):3311–3319.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–120.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Hassan R, Moore KN, et al. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). Journal of Clinical Oncology. 2016;34:2509–2509.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187–187.
   PubMed Web of Science ®Google Scholar
• Ertl HC, Zaia J, Rosenberg SA, et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA advisory committee symposium held June 15, 2010. Cancer Res. 2011;71(9):3175–3181.
   PubMed Web of Science ®Google Scholar
• Tan A, Porcher R, Crequit P, et al. Differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at ClinicalTrials.gov. J Clin Oncol. 2017;35: 1686–1694. Jco2016712109.
   PubMed Web of Science ®Google Scholar